If you’re deep in licensing discussions, walking away can feel almost impossible.
You’ve spent months talking.
You’ve shared information.
You’ve answered technical and commercial questions.
At some point, a quiet pressure sets in:
“We’ve come this far — we can’t walk away now.”
That pressure causes more bad licensing deals than almost anything else.
A real-world pharmaceutical licensing example shows how experienced companies build exit discipline directly into their licensing strategy — and why you should too.
The Real-World Example: Novartis and Argo Biopharma
Novartis entered into a licensing and collaboration agreement with Argo Biopharma focused on siRNA-based therapeutics.
Like many modern pharma licenses, this deal was not structured as an all-or-nothing commitment.
Instead, it included:
- Defined development stages
- Clear decision points
- The ability for Novartis to opt out if milestones or strategic priorities changed
That’s not a failure mode.
That’s intentional design.
Sophisticated licensors and licensees assume uncertainty — and build flexibility accordingly.
The Situation You May Be Facing Right Now
If you’re negotiating a licensing deal, you may recognize this pattern:
- A potential partner shows interest
- Due diligence drags on
- Terms slowly shift in the licensee’s favor
- Exclusivity broadens
- Timelines become vague
And meanwhile, you’re thinking:
- “What if this is our best opportunity?”
- “What if interest disappears if we push back?”
- “What if we never get another shot?”
Those thoughts are understandable — but they’re also where leverage quietly slips away.
Why Experienced Companies Design for the Ability to Walk Away
Companies like Novartis do not assume every licensing deal will reach commercialization.
They assume:
- Markets evolve
- Pipelines change
- Data surprises happen
- Internal priorities shift
So instead of forcing commitment, they design agreements that allow clean exits without destroying future opportunity.
This protects:
- Capital
- Strategic focus
- Optionality
And just as importantly — it prevents IP from being trapped in stalled agreements.
The Strategic Insight You Need to Internalize
Here’s the mindset shift that matters:
A licensing deal that can’t be exited safely is a liability — not an asset.
If a deal:
- Locks up your IP indefinitely
- Has no performance enforcement
- Offers no reversion path
- Depends entirely on goodwill
Then walking away before signing may be the smartest move you make.
Warning Signs You Shouldn’t Ignore
You should seriously consider walking away if:
- Milestones are vague or unenforceable
- Exclusivity is demanded early without compensation
- There’s no consequence for inactivity
- You’re being rushed to sign “before interest fades”
- Your gut tells you alignment isn’t there
These are not negotiation quirks.
They’re structural risks.
What This Means for You as an IP Owner
Walking away does not mean:
- Your IP lacks value
- You failed
- You missed your chance
It often means:
- You protected leverage
- You avoided IP paralysis
- You preserved future licensing options
In licensing, the ability to say no is a strategic advantage.
Companies that rush into deals often spend years trying to unwind them.
How Licensing Consulting Group Helps You Decide When to Proceed — and When to Step Back
One of the most valuable things Licensing Consulting Group (LCG) does for clients is provide an objective perspective during negotiations.
LCG helps you:
- Evaluate whether deal terms align with long-term goals
- Identify hidden risks in exclusivity and scope
- Pressure-test assumptions before signing
- Preserve optionality through structure
- Decide when walking away protects more value than closing
Sometimes the most profitable decision is not signing.
Ask Yourself This Before You Commit
Before agreeing to a licensing deal, ask:
- What happens if this partner deprioritizes my IP?
- Can I reclaim rights if progress stalls?
- Would I still feel good about this deal in two years?
- Am I moving forward strategically — or emotionally?
Those answers matter more than momentum.
Take the Next Step
If you’re in licensing discussions and feel uneasy, that discomfort may be telling you something important.
👉 Schedule a Licensing Strategy Call with Licensing Consulting Group
We’ll review your IP, your current opportunity, and help you determine whether moving forward — or walking away — best protects your long-term interests.
Stay Informed on Real-World Licensing Strategy
The best licensing lessons often come from deals that didn’t get signed.
📩 Subscribe to the Licensing Consulting Group Newsletter to receive:
- Real-world licensing deal breakdowns
- Strategic negotiation insights
- Lessons from active outbound licensing campaigns
This article is part of an ongoing series that breaks down real licensing deals—one strategy at a time—written for IP owners who want practical, experience-based guidance.
Rand Brenner is an IP professional whose passion is helping inventors, startups, and businesses use licensing to turn their IP into income-producing products, services, and technologies. His decades of experience run the gamut from medical devices to food technology to consumer products. He’s licensed some of the biggest Hollywood entertainment blockbusters, including the Batman Movies (1 and 2) and the number one kid’s action TV show, the Mighty Morphin Power Rangers. Rand speaks about licensing and is a featured speaker at investment conferences, trade shows, colleges, and startup events. His first book, Hidden Wealth: The Money-Making Power of Licensing, was released in 2019 and is available on Amazon.com. He’s also a published writer, and his articles have appeared in several prestigious trade magazines, including The Licensing Journal, Intellectual Property Magazine, and License India.
Working Through a Licensing or Commercialization Challenge?
If you have market-ready intellectual property, a licensing campaign that has stalled, or a business opportunity that may benefit from licensing, a short strategy discussion can help clarify the next step.